The downgrade from Overweight to Neutral and the significant reduction in price target from $11 to $5 by JP Morgan analyst Brian Cheng indicate a less optimistic outlook for Mersana Therapeutics. This news is likely to have a negative impact on the stock price in the short term as investors may adjust their positions based on the new rating and price target.